Proteomic exploration of common pathophysiological pathways in diabetes and cardiovascular disease

The epidemiological association between diabetes and cardiovascular disease is well established, but the pathophysiological link is complex and multifactorial. We investigated seven proteins, previously linked to incident diabetes mellitus, and their association with cardiovascular disease and mortality.

[1]  L. Råstam,et al.  Using a Targeted Proteomics Chip to Explore Pathophysiological Pathways for Incident Diabetes– The Malmö Preventive Project , 2019, Scientific Reports.

[2]  A. Siegbahn,et al.  Proteomic Biomarkers for Incident Aortic Stenosis Requiring Valvular Replacement , 2018, Circulation.

[3]  Daniel Levy,et al.  Protein Biomarkers of Cardiovascular Disease and Mortality in the Community , 2018, Journal of the American Heart Association.

[4]  M. Çetin,et al.  Admission Value of Serum Cathepsin D Level Can be Useful for Predicting In-Hospital Mortality in Patients with NSTEMI. , 2017, Acta Cardiologica Sinica.

[5]  Ki-Up Lee,et al.  Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells , 2017, Circulation.

[6]  William R. Hiatt,et al.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations , 2016, Circulation.

[7]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[8]  Zhanqi Cao,et al.  The role of galectin-4 in physiology and diseases , 2016, Protein & Cell.

[9]  G. Guyatt,et al.  Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies , 2016, British Medical Journal.

[10]  B. Hedblad,et al.  High levels of cathepsin D and cystatin B are associated with increased risk of coronary events , 2016, Open Heart.

[11]  D. Bernlohr,et al.  Metabolic functions of FABPs—mechanisms and therapeutic implications , 2015, Nature Reviews Endocrinology.

[12]  G. Vilahur,et al.  A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients1[S] , 2015, Journal of Lipid Research.

[13]  H. Uyarel,et al.  Role of cathepsin D activation in major adverse cardiovascular events and new-onset heart failure after STEMI , 2015, Herz.

[14]  S. Rajagopalan,et al.  DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. , 2015, Circulation research.

[15]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[16]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[17]  H. Møller.  Soluble CD163 , 2012, Scandinavian journal of clinical and laboratory investigation.

[18]  B. Nordestgaard,et al.  Serum soluble CD163 predicts risk of type 2 diabetes in the general population. , 2011, Clinical chemistry.

[19]  V. Gudnason,et al.  Myocardial structure and function by echocardiography in relation to glucometabolic status in elderly subjects from 2 population-based cohorts: a cross-sectional study. , 2010, American heart journal.

[20]  Thomas E. Moritz,et al.  Intensive glucose control and macrovascular outcomes in type 2 diabetes , 2009, Diabetologia.

[21]  Martin Fusek,et al.  Cathepsin D--many functions of one aspartic protease. , 2008, Critical reviews in oncology/hematology.

[22]  E. Tuzcu,et al.  Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. , 2008, Journal of the American College of Cardiology.

[23]  S. Yusuf,et al.  Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose , 2008, Diabetes Care.

[24]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[25]  J. Tu,et al.  Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study , 2006, The Lancet.

[26]  S. Moestrup,et al.  The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. , 2006, Atherosclerosis.

[27]  Fernando Vivanco,et al.  Quest for novel cardiovascular biomarkers by proteomic analysis. , 2005, Journal of proteome research.

[28]  Kai Simons,et al.  Galectin-4 and sulfatides in apical membrane trafficking in enterocyte-like cells , 2005, The Journal of cell biology.

[29]  W. Hundley,et al.  Heart failure prevalence, incidence, and mortality in the elderly with diabetes. , 2004, Diabetes care.

[30]  H. Du,et al.  Lysosomal Enzymes Are Released From Cultured Human Macrophages, Hydrolyze LDL In Vitro, and Are Present Extracellularly in Human Atherosclerotic Lesions , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[31]  M. Huflejt,et al.  Galectin-4 in normal tissues and cancer , 2003, Glycoconjugate Journal.

[32]  A. Tedgui,et al.  Apoptosis in the vasculature: mechanisms and functional importance , 2000, British journal of pharmacology.

[33]  Deepak L. Bhatt,et al.  Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.